Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.63 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.63 |
| ▸ | ALK | Q9UM73 | 7/20 | 0.59 |
| ▸ | CDK19 | Q9BWU1 | 1/20 | 0.59 |
| ▸ | CTSC | P53634 | 3/20 | 0.58 |
| ▸ | AURKA | O14965 | 2/20 | 0.57 |
| ▸ | INSR | P06213 | 4/20 | 0.55 |
| ▸ | IGF1R | P08069 | 4/20 | 0.55 |
| ▸ | CDK2 | P24941 | 2/20 | 0.52 |
| ▸ | CDK4 | P11802 | 1/20 | 0.52 |
| ▸ | BCL6 | P41182 | 1/20 | 0.51 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.50 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.49 |
| ▸ | CCNK | O75909 | 1/20 | 0.49 |
| ▸ | CCND3 | P30281 | 1/20 | 0.49 |
| ▸ | CDK9 | P50750 | 1/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11919318 | 0.86 | EGFR (0.61) | JAK2AURKAINSRIGF1RCDK2 | |
| SCHEMBL29816634 | 0.85 | JAK2 (0.79) | JAK2LRRK2ALKCDK19CTSC | |
| SCHEMBL15391316 | 0.85 | JAK2 (0.79) | JAK2LRRK2ALKCDK19CTSC | |
| SCHEMBL19203857 | 0.84 | ALK (0.56) | ALKAURKAINSRIGF1RCDK2 | |
| SCHEMBL1491753 | 0.82 | AURKA (0.46) | JAK2LRRK2ALKAURKAINSR | |
| SCHEMBL1491757 | 0.82 | ALK (0.83) | ALKAURKAINSRIGF1R | |
| SCHEMBL11916428 | 0.82 | CCNK (0.65) | ALKAURKAINSRIGF1RCDK2 | |
| SCHEMBL11916655 | 0.81 | GSK3A (0.67) | JAK2AURKAINSRIGF1RCDK2 | |
| SCHEMBL19203805 | 0.81 | ALK (0.53) | ALKAURKAINSRIGF1RCDK2 | |
| SCHEMBL11916315 | 0.81 | ALK (0.53) | ALKAURKAINSRIGF1RCDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. | 2017-08-03 | — | — | US | disclosed |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | ARIAD PHARMA INC (US) | 2016-12-29 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2015-08-13 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170218000-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | JAK2 329/4885LRRK2 652/4885ALK 256/4885 |
| US-20150225436-A1 | PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS | MAP3K6, PIK3CA, MAP3K20 | JAK2 305/4885LRRK2 601/4885ALK 265/4885 |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | JAK2 406/4885LRRK2 1090/4885ALK 370/4885 |
| US-20160376297-A1 | Phosphorous Derivatives as Kinase Inhibitors | MAP3K6, PIK3CA, MAP3K20 | JAK2 305/4885LRRK2 601/4885ALK 265/4885 |
| US-20130225527-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | JAK2 361/4885LRRK2 981/4885ALK 316/4885 |
| US-20130225528-A1 | Phosphorus Derivatives as Kinase Inhibitors | PHKA1, PIK3CA, PHKA2 | JAK2 361/4885LRRK2 981/4885ALK 316/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.